Deleted in malignant brain tumors 1 protein is a protein that in humans is encoded by the DMBT1gene.[5][6]
Function
Loss of sequences from human chromosome 10q has been associated with the progression of human cancers. The gene DMBT1 was originally isolated based on its deletion in a medulloblastoma cell line. DMBT1 is expressed with transcripts of 6.0, 7.5, and 8.0 kb in fetal lung and with one transcript of 8.0 kb in adult lung, although the 7.5 kb transcript has not been characterized. The DMBT1 protein is a glycoprotein containing multiple scavenger receptor cysteine-rich (SRCR) domains separated by SRCR-interspersed domains (SID). Transcript variant 2 (8.0 kb) has been shown to bind surfactant protein D independently of carbohydrate recognition. This indicates that DMBT1 may not be a classical tumor suppressor gene, but rather play a role in the interaction of tumor cells and the immune system.[7]
Pattern recognition and potential use of DMBT1 in nanomedicine
At epithelial barriers molecular pattern recognition mechanisms act as minesweepers against harmful environmental factors and thereby play a crucial role in the defense against invading bacterial and viral pathogens. However, it became evident that some of the proteins participating in these host defense processes may simultaneously function as regulators of tissue regeneration when in the extracellular matrix, thus coupling defense functions with regulation of stem cells. Although molecular pattern recognition has complex physiological roles and we just begin to understand its various functions, the simplicity of the underlying principles for recognition of specific classes of molecules may generate novel starting points for nanomedical approaches in drug delivery across epithelial barriers. The protein DMBT1, showed pattern recognition activity for poly-sulfated and poly-phosphorylated ligands, including nucleic acids, and the ability to aggregate ligands. This raises the interesting question in how far these properties can be utilized to assemble nucleic acidpeptide nano-complexes and whether this can be exploited to modulate the pharmacological properties of nucleic acids and/or for nucleic acid delivery to target cells [8] Recently, DMBT1-derived peptides have been successfully harnessed for siRNA intracellular delivery.[9]
^"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^Mollenhauer J, Wiemann S, Scheurlen W, Korn B, Hayashi Y, Wilgenbus KK, von Deimling A, Poustka A (Oct 1997). "DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours". Nat. Genet. 17 (1): 32–9. doi:10.1038/ng0997-32. PMID9288095. S2CID5274568.
Robbe C, Paraskeva C, Mollenhauer J, Michalski JC, Sergi C, Corfield A (2005). "DMBT1 expression and glycosylation during the adenoma-carcinoma sequence in colorectal cancer". Biochem. Soc. Trans. 33 (Pt 4): 730–2. doi:10.1042/BST0330730. PMID16042587.
Rasheed BK, McLendon RE, Friedman HS, Friedman AH, Fuchs HE, Bigner DD, Bigner SH (1995). "Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25". Oncogene. 10 (11): 2243–6. PMID7784070.
Mollenhauer J, Herbertz S, Helmke B, Kollender G, Krebs I, Madsen J, Holmskov U, Sorger K, Schmitt L, Wiemann S, Otto HF, Gröne HJ, Poustka A (2001). "Deleted in Malignant Brain Tumors 1 is a versatile mucin-like molecule likely to play a differential role in digestive tract cancer". Cancer Res. 61 (24): 8880–6. PMID11751412.
Bikker FJ, Ligtenberg AJ, van der Wal JE, van den Keijbus PA, Holmskov U, Veerman EC, Nieuw Amerongen AV (2002). "Immunohistochemical detection of salivary agglutinin/gp-340 in human parotid, submandibular, and labial salivary glands". J. Dent. Res. 81 (2): 134–9. doi:10.1177/154405910208100210. PMID11829014.
Sasaki H, Betensky RA, Cairncross JG, Louis DN (2002). "DMBT1 polymorphisms: relationship to malignant glioma tumorigenesis". Cancer Res. 62 (6): 1790–6. PMID11912156.
Fan X, Muñoz J, Sanko SG, Castresana JS (2002). "PTEN, DMBT1, and p16 alterations in diffusely infiltrating astrocytomas". Int. J. Oncol. 21 (3): 667–74. doi:10.3892/ijo.21.3.667. PMID12168116.
Mueller W, Mollenhauer J, Stockhammer F, Poustka A, von Deimling A (2002). "Rare mutations of the DMBT1 gene in human astrocytic gliomas". Oncogene. 21 (38): 5956–9. doi:10.1038/sj.onc.1205733. PMID12185598. S2CID21374969.